Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential AG and FOLFIRINOX in Resectable Pancreatic Cancer
NCT05679050Phase 2Unknown
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Oct 2022
- Primary completion
- Oct 2024
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label trial of gemcitabine, paclitaxel, oxaliplatin, irinotecan, folinic acid and 1 more in pancreatic cancer (PC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Status: unknown.
02
Drugs
gemcitabinepaclitaxeloxaliplatinirinotecanfolinic acid
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT05679050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05679050.